154 related articles for article (PubMed ID: 7940725)
1. Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation.
Przepiorka D; Ippoliti C; Koberda J; Chan KW; Khouri IF; Fischer HE; Huh YO; Escudier SM; Seong D; Davis M
Transplantation; 1994 Oct; 58(7):858-60. PubMed ID: 7940725
[No Abstract] [Full Text] [Related]
2. [Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature].
Xie XS; Wan DM; Sun H
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):636-7. PubMed ID: 21122422
[No Abstract] [Full Text] [Related]
3. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
4. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Tabayashi T; Yamada K; Takeuchi M
Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation for chronic myelogenous leukemia using unrelated donors: the experience at Huddinge Hospital.
Aschan J; Ringdén O; Ljungman P; Hägglund H; Klaesson S; Dalianis T; Remberger M
Transplant Proc; 1995 Dec; 27(6):3531-2. PubMed ID: 8540086
[No Abstract] [Full Text] [Related]
6. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
Bishop MR; Henslee-Downey PJ; Anderson JR; Romond EH; Marciniak E; Yankey R; Reeves M; Thompson JS
Bone Marrow Transplant; 1996 Oct; 18(4):747-53. PubMed ID: 8899190
[TBL] [Abstract][Full Text] [Related]
7. Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
Varadi G; Ackerstein A; Ben-Neriah S; Nagler A
Bone Marrow Transplant; 1998 Jan; 21(1):93-6. PubMed ID: 9486502
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry.
Ringdén O; Horowitz MM
Transplant Proc; 1989 Feb; 21(1 Pt 3):2989-92. PubMed ID: 2650409
[No Abstract] [Full Text] [Related]
9. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
10. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
Champlin R; Jansen J; Ho W; Gajewski J; Nimer S; Lee K; Territo M; Winston D; Tricot G; Reichert T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
[No Abstract] [Full Text] [Related]
11. Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry.
Bortin MM; Horowitz MM; Gale RP
Nat Immun Cell Growth Regul; 1988; 7(5-6):334-50. PubMed ID: 3065641
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT).
Speiser DE; Hermans J; van Biezen A; Starobinski M; Jeannet M; Jacobsen N; Niederwieser D; Gratwohl A; Apperley JF
Bone Marrow Transplant; 1997 Jun; 19(12):1197-203. PubMed ID: 9208113
[TBL] [Abstract][Full Text] [Related]
13. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
15. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
Huang H; Lin M; Meng H
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation from unrelated donors in chronic myelogenous leukemia.
Ehninger G; Klingebiel T; Schuler U; Einsele H; Schmidt H; Weiss B; Müller CA; Goldmann SF; Grosse-Wilde H; Niethammer D
Semin Hematol; 1993 Jul; 30(3 Suppl 3):49-50. PubMed ID: 8235708
[No Abstract] [Full Text] [Related]
17. Acquired ichthyosis in bone marrow transplant recipients.
Spelman LJ; Strutton GM; Robertson IM; Weedon D
J Am Acad Dermatol; 1996 Jul; 35(1):17-20. PubMed ID: 8682957
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy in human and canine chimeras.
Kolb HJ; Mittermüller J; Günther W; Bartram C; Thalmaier K; Schumm M; Holler E; Lederose G
Bone Marrow Transplant; 1993; 12 Suppl 3():S61-4. PubMed ID: 7510199
[No Abstract] [Full Text] [Related]
20. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
